Search

for
Search:

Research

5 / 1000+ results

research Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome

2 citations , February 2023 in “F&S Reports”

This study found that elagolix treatment did not normalize the ovulatory cycle in patients with polycystic ovarian syndrome.

Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study

research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study

1 citations , August 2021 in “Journal of The American Academy of Dermatology”

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study

research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

66 citations , June 2021 in “Journal of The American Academy of Dermatology”

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas

1 citations , November 2025 in “Neuro-Oncology”

In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.

research Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol

6 citations , May 1986 in “Cancer Chemotherapy and Pharmacology”

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

View more "phase 2 study" in research →

Community Join

5 / 1000+ results

community Phase 3 of pyrilutamide (kx-836) analysis of the efficacy

in Research/Science 11 upvotes 2 years ago

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

community PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed

24 upvotes 2 years ago

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

community Phase II topical dut study - outperforms oral fin with a minor DHT reduction

in Research/Science 61 upvotes 7 months ago

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

community GT20029 Phase 2 results are out

in Treatment 60 upvotes 9 months ago

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

community VDPHL01 phase-2/3 results comparison

in Research/Science 128 upvotes 4 months ago

The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.

View more "phase 2 study" in community →

Learn

9 / 33 results

learn Fluridil

How long does it take to see results with Fluridil in progressive hair loss? No published study measures how long fluridil takes to show a visible change; the single double-blind trial (43 men, 2% fluridil) reported a rise in the proportion of hairs in the growth phase at three and nine months, and community reports describe stabilization rather than regrowth.

learn Setipiprant

What is Setipiprant and how does it differ from DHT blockers like finasteride or dutasteride? Setipiprant blocks the prostaglandin D2 receptor DP2 rather than the DHT pathway that finasteride and dutasteride act on. The one published human trial — a 169-man, 24-week phase 2a study at 2,000 mg a day — reported no statistically significant improvement in hair density over placebo, and setipiprant is not an approved hair-loss medicine anywhere.

learn TDM-105795

How is TDM-105795 used in hair-related products, and is it being explored as a topical treatment, an oral option, or both? TDM-105795 is not sold in any hair product — it is an unapproved experimental compound. The public trial registry shows it has been studied only as a topical scalp solution, in three completed company trials (the largest a 71-participant, 16-week Phase 2); no oral programme is registered, and no peer-reviewed publication exists.

learn PP405

mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

Got small bald patches they say are from stress? PP405 sprays could help bring them back to life. PP405 is an experimental topical gel from Pelage Pharmaceuticals that inhibits the mitochondrial pyruvate carrier; its registered Phase 2 trial (NCT06393452) tested it once daily in 78 adults with pattern hair loss, for safety and tolerability. It is not approved, not for sale, and has not been studied in alopecia areata or stress-related shedding.

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn Overview

learn Epidermal Growth Factor

learn Thymosin Beta 4

learn Scalp Micropigmentation

How long does Scalp Micropigmentation last, and does it need touch-ups over time? Scalp micropigmentation lasts 2 to 8 years and requires touch-ups every 1 to 5 years.

View more "phase 2 study" in learn →

Clinics

1 / 13 results

Hair Systems
Mane PhaseRancho Cucamonga, CA · US

Experts

— no results

Try a deeper search in experts →